Back to Search
Start Over
The regulatory role of DPP4 in atherosclerotic disease.
- Source :
-
Cardiovascular diabetology [Cardiovasc Diabetol] 2017 Jun 15; Vol. 16 (1), pp. 76. Date of Electronic Publication: 2017 Jun 15. - Publication Year :
- 2017
-
Abstract
- The increasing prevalence of atherosclerosis has become a worldwide health concern. Although significant progress has been made in the understanding of atherosclerosis pathogenesis, the underlying mechanisms are not fully understood. Recent studies suggest dipeptidyl peptidase-4 (DPP4), a regulator of inflammation and metabolism, may be involved in the development of atherosclerotic diseases. There has been increasing clinical and pre-clinical evidence showing DPP4-incretin axis is involved in cardiovascular disease. Although the cardiovascular outcome of DPP4 inhibition or incretin analogues has been or being evaluated by several large scale clinical trials, the exact role of DPP4 in atherosclerotic diseases is not completely understood. In the current review, we will summarize the recent advances in direct and indirect regulatory role of DPP4 in atherosclerosis.
- Subjects :
- Animals
Arteries drug effects
Arteries pathology
Atherosclerosis drug therapy
Atherosclerosis pathology
Cardiovascular Agents therapeutic use
Dipeptidyl-Peptidase IV Inhibitors therapeutic use
Humans
Incretins therapeutic use
Arteries enzymology
Atherosclerosis enzymology
Dipeptidyl Peptidase 4 metabolism
Plaque, Atherosclerotic
Signal Transduction drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1475-2840
- Volume :
- 16
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Cardiovascular diabetology
- Publication Type :
- Academic Journal
- Accession number :
- 28619058
- Full Text :
- https://doi.org/10.1186/s12933-017-0558-y